Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
crawford,
Zero shares were bought by any of them..
RegMed Slides Posted (Matt Vincent 6/19/2012) WITH PHASE 2/3 TIMELINES
http://investorstemcell.com/forum/act-main-forum-general-topics-science-press-releases-media/20057.htm
Stemcall,
I am sure he meant the 825k shares sold brought in around $61k
as long as we have unissued shares, we have money available or possible access to more....shares are our currency, always have been..
Silvr,
Why would bankruptcy be a topic/issue when ACT has relatively
no debt?
dianne,
as you can see below the only filings to date are from the SEC attorney's...none of the 7 defendants have responded as of yet.
This will take time and most likely lots of it..
here is the link to my post on last filing below...thanks
http://investorstemcell.com/forum/act-sec-documents-legal-matters-patents/19741.htm
05/30/2012 COMPLAINT against Advanced Cell Technology, Inc., Compass Capital Group, Inc., Mark A. Lefkowitz, Mark A. Lopez, Steven R. Peacock, Shane H. Traveller, Unico, Inc. filed by Securities and Exchange Commission. (Attachments: # 1 Civil Cover Sheet)(ARB) (Entered: 05/31/2012)
05/30/2012 Summons issued as to Advanced Cell Technology, Inc., Compass Capital Group, Inc., Mark A. Lefkowitz, Mark A. Lopez, Steven R. Peacock, Shane H. Traveller, Unico, Inc.. (ARB) (Entered: 05/31/2012)
06/01/2012 RELATED CASE ORDER AND NOTICE of designation under Local Rule 3.05 - track 2. Notice of pendency of other actions due by 6/15/2012. Signed by Judge Mary S. Scriven on 6/1/2012. (APV) (Entered: 06/01/2012)
06/01/2012 INTERESTED PERSONS ORDER. Certificate of interested persons and corporate disclosure statement due by 6/15/2012. Signed by Judge Mary S. Scriven on 6/1/2012. (APV) (Entered: 06/01/2012)
06/14/2012 NOTICE of pendency of related cases re 3 Related case order and notice of designation of track 2 per Local Rule 1.04(d) by Securities and Exchange Commission. Related case(s): No. (Romajas, Suzanne) (Entered: 06/14/2012)
06/14/2012 CERTIFICATE of interested persons and corporate disclosure statement re 4 Interested persons order by Securities and Exchange Commission. (Romajas, Suzanne) (Entered: 06/14/2012)
Graeme,
June 14, 2012 10:06 AM Eastern Daylight Time
Advanced Cell Technology to Present at the 2012 Bio International Convention and the Clinical Outlooks for Regenerative Medicine Meeting
http://www.businesswire.com/news/home/20120614005897/en/Advanced-Cell-Technology-Present-2012-Bio-International
2012 BIO International Convention
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company is presenting at two upcoming conferences: the 2012 Bio International Convention and Clinical Outlooks for Regenerative Medicine meeting, both in Boston, on Tuesday, June 19. The presentations will cover the company’s three ongoing clinical trials using human embryonic stem cell-derived retinal pigment epithelial cells to treat macular degeneration, and other programs.
Gary Rabin, chairman and CEO, will present at the 2012 Bio International Convention on Tuesday, June 19 at 8:15 a.m. EDT, at the Boston Convention & Exhibition Center.
Matthew Vincent, Ph.D., director of business development, will present at the Clinical Outlooks for Regenerative Medicine meeting at 9:15 a.m. EDT on the same date, at the Starr Center, Schepens Eye Research Institute, at 185 Cambridge Street in Boston.
Both presentation slide decks will be available on the conference presentations section of the ACT website
hi louisa,
Wm. Caldwell certainly crossed the line for integrity and just the idea that Gary was CFO at the time really makes me very distrustful of any thing put out there now.
fwiw, Rabin was not the CFO at anytime during that period,
BOD only...thanks
SpleniusCapitis,
To my knowledge all patients ACT has treated to date for SMD/AMD trials are on the immunosuppression regimen.
ACT has no trial for hemangioblast at this time so I am not sure what that has to do with current trials underway?
Here is a clip from the Lancet Publication on ACT's first two patients..
" The immunosuppression regimen included low-dose tacrolimus (target blood concentrations 3–7 ng/mL) and mycophenolate mofetil (ranging from 0·25 to 2·00 g orally per day) a week before the surgical procedure and continued for 6 weeks. At week 6, the regimen calls for discontinuation of tacrolimus and a continuation of mycophenolate mofetil for an additional 6 weeks."
http://download.thelancet.com/flatcontentassets/pdfs/S0140673612600282.pdf
A recent article on the UK patient, Marcus Hilton,
"Hilton is taking the drugs as a precaution and hates the side effects, but hopes he will be able to stop."
http://www.guardian.co.uk/science/2012/jun/04/stem-cell-first-human-trials
SpleniusCapitis,
All injected patients to date have been on an immunosuppression regimen starting one week prior to injection and continuing for 12 weeks after..
like always, it's obvious you don't pay attention. I know of nobody that has been a bigger thorn in ACT's arse than me the past 5 years when it comes to dilution, OS#'s, toxic deals exec compensation etc. I was even labeled a basher on this very board at one time. Given that, you have on many occasions stated the same old tired tune that I work for the Company. If you really believed that one phone call to ACT would straighten you out in short order but I wouldn't expect you to do anything related to due dilligence. Hindsight? No, common sense is more appropriate.
I don't ever give advice on buying or selling a stock like you do. Your the one that needs to explain your posts, not me...enough already, have a good life..
with due respect, you don't have a clue. Can you help me recoup some dollars I lost from following your advice that you gave on 95% of your posts?..:) Or has the wind changed direction for you now?
Do you still think it was "dangerous" not to be heavily invested at 20 cents?..thanks
ACTC is just building a solid base after it's big huge multi million runs, imo. ACTC could pop at anytime and it's very dangerous, imo, not to be heaily invested.
This stock will prove to be a once in a lifetime opportunity for investors, imo. So much points in that direction and their process has already shown to be effective in restoring sight in patients in other countries.
To me, owning this stock and GERN are no brainers.
They both have a ton of patents secured and that means residuals big time, not to mention their own individual potential here and in foreign countries, especially with europe approval apparentl about to happen soon.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58659721
lol, go back and read your first 200+ posts here. Hopefully nobody listened...
louisa,
much more to it than that. SEC has filed suit against ACT
not Caldwells estate so employment contract means nothing.
SEC is holding ACT liable for $3.5MM received as kickbacks from shares that were done under exemption rules which is NOT allowed.
The list goes on..
Start at link below on slide 38
The Illegal Distribution Of Unregistered
Shares Of Advanced Cell Common Stock
http://www.sec.gov/litigation/complaints/2012/comp22381.pdf
126. Overall, for all thirteen settlements, the sales yielded Outboard Investments and the Lefkowitz Related Entities II gross proceeds totaling $10,339,928. Outboard Investments
and /or a Lefkowitz Related Entity II remitted $3,500,000 of the gross process to Advanced Cell through the Intermediary in an effort to conceal the relationship between the payments and the Section 3(a)(10) exchange. Advanced Cell falsely recorded the first $1,500,000 of remittances on its book and records as proceeds from the sale of convertible debentures, which were issued to Transition Holdings and sent to Lefkowitz. However, the debentures were ultimately cancelled and Advanced Cell ultimately gave Transition Holdings exclusive rights to certain non-core technology patents which Caldwell described as patents that relate to non-core technology and that Advanced Cell otherwise would have abandoned or licensed.
Advanced Cell Failed to Timely File Required Current Reports
With The Commission Concerning Its Section 3(a)(10) Settlements
ACT...who do you think?
chuck,
that was a 1st qtr Confernce call. It shouldn't have been a surprise as we have been doing them every quarter end for a year now. Next one will be in August, prior to the 10th...
chuck,
ACT hasn't even made application to Nasdaq yet..eom
ford,
we "officially" had over 2B OS# way back in the first week of
February, almost 3 months ago.
All SHM topic slides are here,
http://www.advancedcell.com/documents/0000/0386/2012-annual-shareholders-meeting---4.26.12---final.pdf
ACT Announces Data & Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt’s Disease Patients in U.S...
Today : Tuesday 24 April 2012
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company’s three ongoing clinical trials, have recently authorized the Company to move forward with enrollment and treatment of additional patients with Stargardt’s disease (SMD). In the U.S. SMD trial, ACT will screen and enroll patients for the second cohort, who, in keeping with trial protocol, will be injected with 100,000 retinal pigment epithelial (RPE) cells - as compared with the 50,000 cell dose used in the patients of the first cohort. The Company has also been approved to treat the final two patients to round out the initial dosing arm in its European trial. The use of pluripotent stem cells to derive RPE cells, and the use of the resulting RPE cells for treating a wide range of macular degenerative disorders, are covered by a robust patent portfolio owned by ACT, including a number of issued broad patents in key world markets.
“DSMB authorization to move to the next higher dosage of cells in our U.S. clinical trial and complete the treatment of the first cohort of patient in our European trial represents yet another significant advancement for our clinical programs,” commented Gary Rabin, chairman and CEO of ACT. “We are pleased with the pace of progress and the continued finding of safety amongst the participants in both the U.S. and European trials. The results so far have been encouraging, and with our SMD programs having been granted ‘orphan’ medicinal product designation in both the U.S. and Europe, we look forward to eventually reaching a stage at which we can further avail ourselves of all the regulatory and financial benefits this designation brings.”
The three procedures comprising the first cohort of patients in the U.S. SMD trial were all conducted at University of California at Los Angeles (UCLA), by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute. The first procedure in the E.U. trial was conducted at Moorfields Eye Hospital in London, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London.
“We are gratified to be moving to the next stage in both of our SMD trials,” commented Robert Lanza, M.D., ACT’s chief scientific officer. “We remain very encouraged by the preliminary data in the first four SMD patients treated with the lowest dose of RPE cells at UCLA and Moorfields Eye Hospital. We are doubling the number of cells that will be transplanted in the next group of patients in the U.S. trial. We will be anxious to see if the higher dosage of RPE cells will impact visual function and photoreceptor rescue.”
ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration. Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry-AMD or Stargardt's macular dystrophy (SMD) at 12 months, the study’s primary endpoint. On January 20, 2012, the first SMD patient enrolled in the Company’s U.K. clinical trial was treated at Moorfields Eye Hospital in London. The final patient of the first cohort in the company’s SMD trial in the U.S. was treated on February 13, 2012.
Further information about patient eligibility for the dry AMD study and the concurrent study on SMD is also available on www.clinicaltrials.gov; ClinicalTrials.gov Identifiers: NCT01345006, NCT01469832 and NCT01344993.
elk,
This was from last annual meeting, you could give it a shot
I guess..
Investors may submit questions to jyoung@ceocast.com with the subject line "Shareholder Meeting" up until 4 p.m. eastern time on Wednesday, June 8th. The Company will address as many questions as time permits. Investors may also email questions to the same address while the presentation is ongoing, and if time permits, those questions will be addressed as well.
http://www.advancedcell.com/news-and-media/press-releases/advanced_cell_technology_to_webcast_2011_annual_stockholders_meeting/index.asp
elk,
MARLBOROUGH, Mass. — Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will webcast its Annual Shareholders’ Meeting to be held on Thursday, April 26th at the Hyatt Regency Suites, Palm Springs, 285 N. Palm Canyon Drive, Palm Springs, Calif.. The meeting is open to shareholders of record as of March 1, 2012. The webcast will begin at 9 a.m. PDT, after the Company completes the formal portion of the meeting, where results of proxy voting will be announced. At that time, members of the management team will deliver a Company presentation and address questions from shareholders. Questions will be taken from both members of the live audience as well as electronically from the webcast.
ACT Announces Second Patient with Dry AMD Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells
ACT Announces Second Patient with Dry AMD Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells
Two Clinical Trial Sites Now Approved to Participate in Clinical Trial for Dry AMD
MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the second patient was dosed in the Company’s Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient is recovering uneventfully.
“We are very pleased to announce that the treatment of the second dry AMD patient went very well, without any complications,” said Gary Rabin, chairman and CEO of ACT. “We are delighted with our ongoing progress in all of our clinical trials using our stem cell-derived RPE cells to treat forms of macular degeneration. So far, there have not been any complications or side effects due to the stem cell-derived RPE cells, and we will continue monitoring the patients for safety, tolerability and efficacy of this therapy.”
The dry AMD trial is one of three clinical trials being carried out by the company in the U.S. and in Europe. Each trial will enroll 12 patients, with cohorts of three patients in an ascending dosage format. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or Stargardt's macular dystrophy (SMD) at 12 months, the study’s primary endpoint. Preliminary results relating to both early safety and biological function for the first two patients in the United States, one SMD patient and one dry AMD patient, were recently reported in The Lancet.
Further information about patient eligibility for the dry AMD study and the concurrent study on SMD is also available on www.clinicaltrials.gov; ClinicalTrials.gov Identifiers: NCT01345006 and NCT01344993.
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date;
http://www.sec.gov/Archives/edgar/data/1289496/000135448812001528/cbai_nt10k.htm
Laser was citing the numbers, not me. I am not a believer of the FINRA short numbers as I have posted several times..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=73711358
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=73753037
interstate,
I would assume they are issuing shares quarterly for the bolded section below..
Non-executive members of the Company's Board of Directors receive (1) an initial grant of 100,000 shares of common stock, (2) an annual grant of 500,000 shares of common stock, (3) an annual grant of 500,000 stock options, (4) an annual retainer of $40,000 (payable quarterly), and (5) a cash payment for attendance at each board meeting in the amount of $2,000 for in-person meetings and $1,000 for telephonic meetings. Regarding members of the Company's Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, the Chair receives a payment of $1,500 per meeting and the regular members receive $1,000 per meeting. Each independent director is entitled to receive payment of the directors' fees in the form of shares of the Company's Common Stock valued at 150% of the actual directors' fees due and payable. The fee structure for the directors was established and approved by the Compensation Committee and ratified by the full Board of Directors effective August 1, 2011.
louisa,
actually you will note the price is 0, these are granted shares
not bought..thanks
louisa,
Perry is an ACT BOD
Gregory D. Perry
Gregory Perry is EVP & CFO at ImmunoGen, Inc. He joined ImmunoGen in January 2009 as Senior Vice President and Chief Financial Officer and was promoted to his current position in March 2011. Before joining ImmunoGen, Mr. Perry was CFO of Elixir Pharmaceuticals, Inc., where he was extensively involved in partnering and fundraising activities.
http://www.advancedcell.com/company/leadership-team/board-of-directors/
OS# is 2,072,546,302 as of April 3
March 22nd it was OS# 2,039,174,522
Increase of 33,571,780 in about one week
1 USD = 3.70679 ILS
example:
(Identa sales for 2011) 787,401.00 ILS = 212,461.16 USD
http://www.xe.com/ucc/convert/?Amount=787401&From=ILS&To=USD
locks,
non-accekerated filers, like CBAI, have 90 days from their year end to file 10K. This year Feb had 29 days.
Therefore the filing is due March 30, not the 31st as most years.
January..31 days
February.29 days
March....30 days
Total 90 days
Non-Accelerated Filers:
10-K: for Fiscal Year Ended 12/31/11 due Friday, March 30, 2012
Non-Accelerated Filers
Form 10-K/10-KSB 90 days after end of fiscal year end
EDGAR Filing Deadlines
http://www.secfile.net/SEC_calendar.htm#Filing_deadline_calculator